Project description:To understand the molecular change occurring in the atria during obstructive sleep apnea, we have implemented a rat model of OSA involving the surgical implantation of a tracheal obstructive device, allowing the rats to remain conscious and free-roaming throughout 2 weeks of apnea administration. Rats were divided into severe and moderate apnea groups, receiving a 23 second or 13 second apneas per minute, respectively. The two-dimensional polyacrylamide gel electrophoresis (2D PAGE) of atrial homogenates to compare the dysregulations in the protein pattern in severe and moderate apnea when compared to control.
Project description:Obstructive sleep apnoea (OSA), a type of chronic intermittent hypoxia with increasing global prevalence, constitutes a multisystemic disorder often associated with cardiovascular and metabolic disorders.In total, 142 plasma samples were acquired: 50 from controls (CON), 45 from mild/moderate OSA (M-OSA) patients, and 47 from severe OSA (S-OSA) patients.Proteomic and metabolic signatures significantly differed among S-OSA, M-OSA, and CON samples.Omics analysis revealed the characteristics of OSA and uncovered potential mechanisms by which diabetes mellitus and cardiovascular disease risks are increased in OSA. These results might also provide new diagnostic biomarkers for OSA and the identification of severe cases.
Project description:Obstructive Sleep Apnea is a sleep-related breathing disorder. Differential methylation analysis was conducted to evaluate differentially methylated regions across the chromosomes in patients with severe OSA compared to healthy subjects. We further evaluated how these differentially methylated regions were altered with long-term (24 months) continuous positive airway pressure treatment.
Project description:Obstructive Sleep Apnea, a sleep related breathing disorder RNA sequencing analysis was conducted to evaluate differentially expressed genes in patients with severe OSA compared to healthy subjects. We further evaluated how these differentially expressed genes and associated pathways altered with short-term (4 months) vs. long-term (24 months) continuous positive airway pressure treatment.
Project description:Therefore, we extended our investigation into OSA patients with long-term continuous positive airway pressure (CPAP) treatment, hypertension, or excessive daytime sleepiness (EDS) by analyzing whole-genome gene expression profiles of PBMC in three comparisons: (1) treatment-naïve moderate to very severe OSA patients versus subjects with primary snoring; (2) moderate to very severe OSA patients with hypertension or EDS versus those without hypertension or EDS, respectively; (3) treatment-naïve very severe OSA patients versus those receiving at least one year of adequate CPAP treatment. We analyzed whole-genome gene expression profiles of peripheral blood mononuclear cells from 48 patients with sleep-disordered breathing stratified into four groups: primary snoring (PS), moderate to severe OSA (MSO), very severe OSA (VSO), and very severe OSA patients with long-term continuous positive airway pressure (CPAP) treatment (VSOC).
Project description:Three healthy pregnant women without obstructive sleep apnea (OSA) (C), three pregnant women with mild OSA (O), and three pregnant women with moderate (MO) OSA were enrolled to identify serum diagnostic biomarkers-associated with the severity of OSA during pregnancy. Differentially expressed proteins (DEPs) among control (C), mild (O), and moderate (MO) OSA groups were identified. Bioinformatics analysis was conducted to discover the underlying functions, pathways and networks of the proteins. Furthermore, receiver operating characteristic curve (ROC) curve was used to assess the diagnostic value of the identified DEPs. A total of 141, 29, and 103 DEPs were identified among the three groups. C1R and A2M were identified as continuously upregulated proteins, and the levels of C1R and A2M were related with the severity of OSA.
Project description:Genome wide DNA methylation profiling of obstructive sleep apnea (OSA) patients and healthy subjects. The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in peripheral blood mononuclear cell samples. Samples included 8 normal subjects and 16 patients with obstructive sleep apnea syndrome. Bisulphite converted DNA from the 21 samples were hybridized to the Illumina Infinium 27k Human Methylation Beadchip v1.2
Project description:Genome wide DNA methylation profiling of obstructive sleep apnea (OSA) patients and healthy subjects. The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in peripheral blood mononuclear cell samples. Samples included 8 normal subjects and 16 patients with obstructive sleep apnea syndrome.